SCHEMBL16375392

SCHEMBL16375392

O=C(O)CCCCC(CCSCc1ccc2ccccc2c1)SCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.50
▸ CYP2C19 P33261 2/20 0.48
▸ EPHX1 P07099 2/20 0.41
▸ PTGER1 P34995 1/20 0.40
▸ PTGER4 P35408 1/20 0.40
▸ PTGER3 P43115 1/20 0.40
▸ PTGER2 P43116 1/20 0.40
▸ PLA2G4B P0C869 1/20 0.40
▸ CYP2D6 P10635 1/20 0.39
▸ FTO Q9C0B1 1/20 0.39
▸ FFAR1 O14842 1/20 0.39
▸ HTT P42858 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38
▸ MC4R P32245 1/20 0.37
▸ MC5R P33032 1/20 0.37
▸ MC3R P41968 1/20 0.37
▸ MC1R Q01726 1/20 0.37
▸ MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10307786 0.98 CYP1A2 (0.52) CYP1A2CYP2C19EPHX1PLA2G4BCYP2D6
Cpi 613 SCHEMBL13333201 0.89 CYP2C19 (0.59) CYP2C19PTGER1PTGER4PTGER3PTGER2
Cpi 613 SCHEMBL1062218 0.89 CYP2C19 (0.59) CYP2C19PTGER1PTGER4PTGER3PTGER2
SCHEMBL22299081 0.88 CYP2C19 (0.58) CYP2C19PTGER1PTGER4PTGER3PTGER2
SCHEMBL17381514 0.88 CYP2C19 (0.58) CYP2C19PTGER1PTGER4PTGER3PTGER2
SCHEMBL10307745 0.84 CYP2C19 (0.50) CYP2C19PTGER1PTGER4PTGER3PTGER2
SCHEMBL10307764 0.81 CYP2C19 (0.47) CYP2C19PTGER1PTGER4PTGER3PTGER2
SCHEMBL20395792 0.81 CYP2C19 (0.63) CYP2C19PTGER1PTGER4PTGER3PTGER2
SCHEMBL10307777 0.81 CYP2C19 (0.52) CYP2C19EPHX1PTGER1PTGER4PTGER3
SCHEMBL10307784 0.81 CYP2C19 (0.44) CYP2C19EPHX1PTGER1PTGER4PTGER3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150011633-A1 PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES CORNERSTONE PHARMACEUTICALS, INC. (US) 2015-01-08 — — US disclosed
US-20150011633-A1 PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES CORNERSTONE PHARMACEUTICALS, INC. (US) 2015-01-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150011633-A1 PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES LIPA, LIPC, TTPA CYP1A2 1104/4885CYP2C19 295/4885EPHX1 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback